TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an announcement.
Botanix Pharmaceuticals Limited announced the quotation of 200,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 3, 2025. This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders by expanding its financial base and operational capabilities.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company aims to address unmet needs in skin diseases and infections through innovative therapeutic solutions.
Average Trading Volume: 15,090,331
Technical Sentiment Signal: Sell
Current Market Cap: A$284.4M
See more data about BOT stock on TipRanks’ Stock Analysis page.